Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1998 3
1999 2
2000 6
2002 4
2003 2
2004 2
2005 6
2006 5
2007 7
2008 7
2009 4
2010 2
2011 3
2012 7
2013 4
2014 7
2015 5
2016 3
2017 2
2018 4
2019 7
2020 4
2021 3
2022 1
2023 3
2024 3
2025 4
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Safety of Testosterone-Replacement Therapy.
Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Study Investigators. Lincoff AM, et al. N Engl J Med. 2023 Jul 13;389(2):107-117. doi: 10.1056/NEJMoa2215025. Epub 2023 Jun 16. N Engl J Med. 2023. PMID: 37326322 Clinical Trial.
METHODS: In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who reported symptoms of hypogonadism and had two fasting testosterone …
METHODS: In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age wh …
Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial.
Gieles NC, Kroon MAGM, Both S, Heijboer AC, Kreukels BPC, den Heijer M. Gieles NC, et al. Eur J Endocrinol. 2024 Aug 30;191(3):279-287. doi: 10.1093/ejendo/lvae103. Eur J Endocrinol. 2024. PMID: 39163572 Free article. Clinical Trial.
OBJECTIVE: Transgender women who underwent gonadectomy have lower serum testosterone concentrations than cisgender women. ...This dose was then continued for 8 weeks. METHODS: Participants applied daily transdermal testosterone 2% gel (To …
OBJECTIVE: Transgender women who underwent gonadectomy have lower serum testosterone concentrations than cisgender women …
Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
Dichtel LE, Carpenter LL, Nyer M, Mischoulon D, Kimball A, Deckersbach T, Dougherty DD, Schoenfeld DA, Fisher L, Cusin C, Dording C, Trinh NH, Pedrelli P, Yeung A, Farabaugh A, Papakostas GI, Chang T, Shapero BG, Chen J, Cassano P, Hahn EM, Rao EM, Brady RO Jr, Singh RJ, Tyrka AR, Price LH, Fava M, Miller KK. Dichtel LE, et al. Am J Psychiatry. 2020 Oct 1;177(10):965-973. doi: 10.1176/appi.ajp.2020.19080844. Epub 2020 Jul 14. Am J Psychiatry. 2020. PMID: 32660299 Free PMC article. Clinical Trial.
OBJECTIVE: Low-dose testosterone has been shown to improve depression symptom severity, fatigue, and sexual function in small studies in women not formally diagnosed with major depressive disorder. The authors sought to determine whether adjunctive low-dos …
OBJECTIVE: Low-dose testosterone has been shown to improve depression symptom severity, fatigue, and sexual function in small …
Low-dose transdermal testosterone augmentation therapy improves depression severity in women.
Miller KK, Perlis RH, Papakostas GI, Mischoulon D, Losifescu DV, Brick DJ, Fava M. Miller KK, et al. CNS Spectr. 2009 Dec;14(12):688-94. doi: 10.1017/s1092852900023944. CNS Spectr. 2009. PMID: 20394176 Free PMC article. Clinical Trial.
METHODS: Low-dose transdermal testosterone (300 mcg/day, Intrinsa, Procter and Gamble Pharmaceuticals) was administered to nine women with treatment-resistant depression in an 8 week open-label pilot protocol. ...CONCLUSION: These preliminary pilot dat …
METHODS: Low-dose transdermal testosterone (300 mcg/day, Intrinsa, Procter and Gamble Pharmaceuticals) was administered …
The impact of transdermal testosterone treatment on quality of life in women with diminished ovarian reserve: secondary analysis of a randomized controlled trial.
Leathersich SJ, Davis SR, García Martínez S, Blockeel C, Martínez F, Gosálvez A, Humaidan P, de la Fuente L, Fàbregues F, Pinborg A, Stoop D, Polyzos NP. Leathersich SJ, et al. Hum Reprod. 2026 Feb 1;41(2):231-238. doi: 10.1093/humrep/deaf233. Hum Reprod. 2026. PMID: 41461161 Clinical Trial.
STUDY QUESTION: Does transdermal testosterone treatment improve fertility-related quality of life (QOL) in women with diminished ovarian reserve (DOR)? SUMMARY ANSWER: Transdermal testosterone for 9 weeks at a dose of 5.5 mg per day did n …
STUDY QUESTION: Does transdermal testosterone treatment improve fertility-related quality of life (QOL) in women with d …
Reproductive depression.
Studd J, Nappi RE. Studd J, et al. Gynecol Endocrinol. 2012 Mar;28 Suppl 1:42-5. doi: 10.3109/09513590.2012.651932. Gynecol Endocrinol. 2012. PMID: 22394303 Review.
The critical time to prevent long-term mood problems is the correct treatment of postnatal depression. In women with low energy and libido, often a side effect of antidepressants, the addition of transdermal testosterone is useful. These women with rep …
The critical time to prevent long-term mood problems is the correct treatment of postnatal depression. In women with low energy and l …
Androgens in women.
Davison SL, Davis SR. Davison SL, et al. J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):363-6. doi: 10.1016/s0960-0760(03)00204-8. J Steroid Biochem Mol Biol. 2003. PMID: 12943723 Review.
Testosterone treatment is being developed for women in the form of transdermal patches, gels or cream, with percutaneous implants in common usage in some countries. ...Beneficial effects of testosterone treatment in post-menopausal women with lo …
Testosterone treatment is being developed for women in the form of transdermal patches, gels or cream, with percutaneou …
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA. Shifren JL, et al. N Engl J Med. 2000 Sep 7;343(10):682-8. doi: 10.1056/NEJM200009073431002. N Engl J Med. 2000. PMID: 10974131 Free article. Clinical Trial.
We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced menopause. ...CONCLUSIONS: In women who have undergone oophorectomy and hysterectomy, transdermal testosterone improve …
We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced …
Development of a single-dose intranasal testosterone administration paradigm for use in men and women.
Luberti FR, Reside TL, Bonin PL, Carré JM. Luberti FR, et al. Horm Behav. 2021 Nov;136:105046. doi: 10.1016/j.yhbeh.2021.105046. Epub 2021 Sep 3. Horm Behav. 2021. PMID: 34488062
Most of these single-dose administration studies have so far used (1) single-sex samples and (2) varying modes of testosterone administration (intramuscular, transdermal, sublingual, and intranasal) that produced vastly different dose-res …
Most of these single-dose administration studies have so far used (1) single-sex samples and (2) varying modes of testoster …
A Randomized Placebo-Controlled Trial of Low-Dose Testosterone Therapy in Women With Anorexia Nervosa.
Kimball A, Schorr M, Meenaghan E, Bachmann KN, Eddy KT, Misra M, Lawson EA, Kreiger-Benson E, Herzog DB, Koman S, Keane RJ, Ebrahimi S, Schoenfeld D, Klibanski A, Miller KK. Kimball A, et al. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4347-4355. doi: 10.1210/jc.2019-00828. J Clin Endocrinol Metab. 2019. PMID: 31219558 Free PMC article. Clinical Trial.
SETTING: Clinical research center. PARTICIPANTS: Ninety women, 18 to 45 years, with AN and free testosterone levels below the median for healthy women. ...CONCLUSION: Low-dose testosterone therapy for 24 weeks was associated with less weight gai …
SETTING: Clinical research center. PARTICIPANTS: Ninety women, 18 to 45 years, with AN and free testosterone levels below the …
101 results